New investors Alzheimer's Drug Discovery Foundation, Starbloom Capital, IAG Capital and WS Investment Company (Wilson Sonsini's venture arm) joined the round. The series B funding brings the total amount raised since inception to USD 93m.
In addition to the financing, Dr. Rick Kuntz, MD, MSc, former senior vice president, Chief Medical and Scientific officer of Medtronic and Helen Liang, Founder & Managing Partner at FoundersX, will join Cognito's board of directors.
Dr. Kuntz spent 17 years at Medtronic, where he initially led the company's neuromodulation business and then corporate technology and clinical research.
Prior to Medtronic, he was the founder and chief scientific officer of the Harvard Clinical Research Institute, now the Baim Institute, a university-based contract research organization which coordinates National Institutes of Health and industry clinical trials with the US Food and Drug Administration.
The funding will advance Cognito's pivotal study of its non-invasive neuromodulation device, which delivers proprietary gamma frequency light and sound stimulation intended to treat Alzheimer's Disease. In a prior Phase 2 clinical trial, Cognito's device demonstrated a significant slowing in functional and cognitive decline in the treatment group, as well as a significant decline in brain atrophy over a six-month period.
To further demonstrate the efficacy of the device, Cognito is currently enrolling patients in its pivotal clinical trial HOPE for Alzheimer's Disease, across approximately 50 clinical centers in the United States with a target enrollment of 500 patients.
Cognito's device is limited by United States law to investigational use only and is not available for sale.
Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden.
The company's lead therapy is currently in a pivotal study in Alzheimer's Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study